University of Houston: Targeted Delivery of Highly Toxic Anti-Cancer Drug to Brain Tumors
February 24, 2021
February 24, 2021
HOUSTON, Texas, Feb. 24 (TNSJou) -- The University of Houston issued the following news release:
With a survival rate of only five years, the most common and aggressive form of primary brain tumor, glioblastoma multiforme, is notoriously hard to treat using current regimens that rely on surgery, radiation, chemotherapy and their combinations.
"Two of the major challenges in the treatment of gliomas include poor transport of chemotherapeutics across the blood brain . . .
With a survival rate of only five years, the most common and aggressive form of primary brain tumor, glioblastoma multiforme, is notoriously hard to treat using current regimens that rely on surgery, radiation, chemotherapy and their combinations.
"Two of the major challenges in the treatment of gliomas include poor transport of chemotherapeutics across the blood brain . . .